Effect of oxytocin infusion on secretion of progesterone and luteinizing hormone and the concentration of uterine oxytocin receptors during the periovulatory period in cloprostenol-treated ewes.
Oxytocin infusions were initiated on day 10 of the oestrous cycle in ewes, and luteal regression was induced by injection of 100 micrograms cloprostenol on day 12. Blood samples were collected at frequent intervals via an indwelling jugular vein cannula to measure concentrations of progesterone and luteinizing hormone (LH) during the luteal and follicular phases in saline (n = 6) and oxytocin (n = 5) infused animals. The oxytocin infusion maintained peripheral plasma concentrations of 53 +/- 3.2 pg oxytocin ml-1 (mean +/- SEM) compared with values of about 1 pg ml-1 during oestrus in control ewes. Oxytocin infusion had no effect on luteal phase progesterone concentrations, the timing of luteolysis, basal luteinizing hormone (LH) secretion, LH pulse frequency, or the timing or height of the LH surge. Treated ewes came into oestrus significantly earlier than controls (P < 0.05) but ovulated normally. Uterine samples collected 96 h after cloprostenol injection (approximately day 2 of the cycle) showed that oxytocin receptor concentrations were significantly higher in the endometrium in ewes that had been given a 5 day oxytocin infusion than in control animals (556 and 262 fmol mg-1 protein, respectively: geometric means from ANOVA, P < 0.001), whereas myometrial receptor concentrations were not affected (113 and 162 fmol mg-1 protein, respectively). We conclude that the previously reported delay in luteal development caused by oxytocin infusion (Wathes et al., 1991) is not due to the inhibition or delay of ovulation, but must instead occur via a direct influence on the developing corpus luteum.(ABSTRACT TRUNCATED AT 250 WORDS)
Wathes
D C
DC
Department of Anatomy, School of Medical Sciences, Bristol, UK.
Matthews
E L
EL
Ayad
V J
VJ
D000704:Analysis of Variance; D000818:Animals; D003008:Cloprostenol / Q000494:pharmacology; D003338:Corpus Luteum / Q000187:drug effects; D004717:Endometrium / Q000187:drug effects / Q000378:metabolism; D004971:Estrus / Q000187:drug effects; D005260:Female; D005498:Follicular Phase / Q000097:blood / Q000187:drug effects; D015918:Infusion Pumps, Implantable; D007262:Infusions, Intravenous; D008183:Luteal Phase / Q000097:blood / Q000187:drug effects; D007986:Luteinizing Hormone / Q000378:metabolism*; D003341:Luteolysis; D009215:Myometrium / Q000187:drug effects / Q000378:metabolism; D010060:Ovulation / Q000187:drug effects; D010121:Oxytocin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000378:metabolism*; D011863:Radioimmunoassay; D018045:Receptors, Oxytocin / Q000096:biosynthesis*; D012756:Sheep; D014599:Uterus / Q000187:drug effects* / Q000378:metabolism
D018045:Receptors, Oxytocin; D003008:Cloprostenol; D011374:Progesterone; D010121:Oxytocin; D007986:Luteinizing Hormone